Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 25, 2003. The report primarily details changes in directors' interests in the company's ordinary shares and American Depositary Receipts (ADRs), as well as a notification regarding a change in major shareholding interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions and share ownership disclosures rather than financial performance metrics.
Material Changes
The following material changes in share interests were reported:
- Director Share Acquisitions: Mr. J D Coombe increased his interest by 154 Ordinary Shares at £12.08 per share via dividend reinvestment. Dr. J P Garnier increased his interest by 376,942 Ordinary Share ADRs at an average price of $39.107 per share via dividend reinvestment.
- Trust Transactions: The GlaxoSmithKline Employee Trust (GSK Trust) sold 1,476 Ordinary Shares at £12.25 per share and transferred 1,411 shares to a participant of the Glaxo Wellcome 1999 Long Term Incentive Plan. Additionally, the Trust transferred 86,482 shares to participants of the SmithKline Beecham 1991 Share Option Plan and 25,584 shares to participants of the SmithKline Beecham 1989 Share Option Plan.
- ADR Reinvestment: Directors Mr. D F McHenry and Mr. J H McArthur acquired beneficial interests in ADRs (0.3852 and 50.7086 respectively) at $39.3237 per ADR through the US Global BuyDirect Plan.
- Major Interest Notification: Abacus Financial Services Group Limited notified the company that, effective April 24, 2003, it no longer holds a notifiable interest in the company's Ordinary Shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory disclosure of share ownership changes and does not contain forward-looking statements or risk assessments.
Key Facts for Investor Verification
- Verify the impact of the GSK Trust transactions on the total number of shares outstanding and potential dilution.
- Confirm the current aggregate shareholding of directors Mr. J D Coombe and Dr. J P Garnier following the reported increases.
- Investigate the reason for Abacus Financial Services Group Limited ceasing to hold a notifiable interest in the company.
- Review the terms of the SmithKline Beecham 1989 and 1991 Share Option Plans and the Glaxo Wellcome 1999 Long Term Incentive Plan to understand the vesting conditions for the transferred shares.